pazopanib + gemcitabine + docetaxel (Memorial Sloan Kettering Cancer Center)

The combination of pazopanib, gemcitabine, and docetaxel was an investigational neoadjuvant regimen evaluated by Memorial Sloan Kettering Cancer Center (MSKCC) for the treatment of high-grade, localized extremity soft tissue sarcoma. Pazopanib is an oral multitargeted tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), platelet-derived growth factor receptors (PDGFR-α and -β), and c-Kit, primarily acting as an antiangiogenic agent. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by replacing cytidine during DNA replication and inhibiting ribonucleotide reductase. Docetaxel is a taxane that promotes microtubule assembly and inhibits disassembly, leading to cell cycle arrest. A Phase Ib/II trial (NCT01507480) was initiated to assess the safety and efficacy of this triplet therapy prior to surgical resection; however, the study was terminated early due to slow patient accrual and significant toxicities, including hepatotoxicity.

Other names

gemcitabine, docetaxel, and pazopanib